Introduction
============

The prevalence of type 2 diabetes is increasing worldwide, with the number of affected individuals expected to double by 2050.[@b1-ppa-7-1007] Diabetes is a leading cause of kidney failure, blindness, leg amputation, and myocardial infarction. There is evidence that early control of blood glucose can help prevent these diabetes-related complications.[@b2-ppa-7-1007] Current treatment is based on a stepwise approach starting with changes in lifestyle and progressively introducing oral antidiabetic agents, with the aim of maintaining glycated hemoglobin (HbA~1c~) levels below a defined target. This target is defined according to the patient's characteristics.[@b3-ppa-7-1007]--[@b5-ppa-7-1007] In the current paradigm, insulin is usually considered to be the last step in treatment intensification.

Prescribing insulin at later stages of type 2 diabetes disease progression has recently been challenged, arguing that a delay in insulin initiation may affect the patient's long-term prognosis. Indeed, it is well known that elevated fasting plasma glucose levels are primarily due to an increase in hepatic glucose production, secondary to an insufficient endogenous insulin secretion needed to overcome insulin resistance.[@b6-ppa-7-1007] Furthermore, there is a well documented decline in insulin secretion due to beta cell exhaustion, and it has been suggested that early use of insulin may suppress inflammation and glucolipotoxicity, which results in autoaggravation of the disease.[@b7-ppa-7-1007]

However, early introduction of insulin may represent a challenge with regard to the well known "psychological insulin resistance" status affecting both patients and doctors. This results in delayed insulin prescription when it would be appropriate according to current guidelines. Psychological insulin resistance,[@b8-ppa-7-1007] which represents a typical case of clinical inertia,[@b9-ppa-7-1007]--[@b14-ppa-7-1007] may be due in part, on the side of the doctor, to the supposed effect of insulin treatment on patients' quality of life which may hinder future adherence.[@b15-ppa-7-1007]--[@b19-ppa-7-1007] On the other hand, nonadherence to long-term therapies also represents a barrier to the efficiency of care,[@b20-ppa-7-1007]--[@b22-ppa-7-1007] even if it seems that doctors' clinical inertia is actually more frequent than patient nonadherence.[@b23-ppa-7-1007]

In this context, the objective of this study using data from the National Health and Wellness Survey (NHWS) carried out in France was to identify the intrinsic and extrinsic determinants of insulin prescription, and more specifically of early insulin initiation (being defined as 5 years or less following diagnosis) in type 2 diabetes, and to evaluate the impact of insulin therapy on mental and physical quality of life and patient adherence.

Materials and methods
=====================

National Health and Wellness Survey sample
------------------------------------------

The study sample and data were taken from the 2008, 2010, and 2011 waves (2008, n = 15,457; 2010, n = 15,501; 2011, n = 15,000) of the French NHWS. The NHWS is an annual Internet-based questionnaire developed by Kantar Health and the Ailment Panel of Lightspeed Research. It is a cross-sectional study of subjects aged 18 years or older, conducted with a strictly identical methodology for the 3 years (2008,2010, and 2011). Only a small proportion of individuals from the sample were common between waves (approximately one in five) and data from recent participation were retained.

The primary objective of the NHWS is to provide a comprehensive database of epidemiological and treatment information, health care attitudes, behaviors, demographic and disease characteristics, and health-related outcomes. The 2011, 2010, and 2008 surveys employ a stratified random sample (with both sex and age group quotas), in order to replicate the demographic composition of each of the population of each individual country. Representation of NHWS data has been validated against reliable sources, including government agencies' health statistics and nonaffiliated third parties. Results are projected to reflect the total population in each country using known population characteristics. In France, data are weighted by sex and age using the United States Bureau of the Census and Organization for Economic Cooperation and Development.

A self-administered questionnaire is completed by a sample population identified through a web-based consumer panel. All data from the NHWS are self-reported by participating respondents. All respondents received and agreed with the informed consent form provided, and the study was approved by the Essex Institutional Review Board (Lebanon, NJ, USA). Of the total 45,958 persons recruited (three waves deduped study sample), 1,933 respondents were identified as reporting a physician diagnosis of type 2 diabetes, comprising 591 from the 2008 wave, 649 from 2010, and 693 from 2011 (respectively 3.8%, 4.2%, and 4.3% of the general population of adults). All unique respondents diagnosed with type 2 diabetes currently using insulin or oral bitherapy or tritherapy at the time of assessment were included (n = 713, see [Table 1](#t1-ppa-7-1007){ref-type="table"}); this choice was justified by the fact that, both according to current guidelines and as a result of doctors' and patients' psychological insulin resistance, patients treated with dual therapy or tritherapy have a greater likelihood of being switched to insulin than those treated with monotherapy.

Measures and survey instruments
-------------------------------

### Independent variables

We first compared all patients on bitherapy or tritherapy (n = 443) and all insulin users (n = 270). Second, we compared early and late initiation of insulin: based on calculation of the number of years between diagnosis of type 2 diabetes and initiation of insulin, with early insulin defined as 5 years or less (n = 143). The control group (n = 124) consisted of those patients who were prescribed insulin later. Third, another independent variable of interest was the duration of insulin use, using a median split of the number of years using insulin, ie, 5 years or less versus 6 years or more ([Table 1](#t1-ppa-7-1007){ref-type="table"}).

### Covariates

Regardless of how early initiation is defined, great care must be taken in isolating the effect of early initiation or beginning insulin on health outcomes, given the cross-sectional, observational nature of the NHWS. Insulin can be initiated for a variety of reasons as physicians attempt to manage risk in their patients. Irrespective of outcomes, the model included the following predictors: age/age at diagnosis, duration of type 2 diabetes, sex, education, household income, and employment type (see [Table 2](#t2-ppa-7-1007){ref-type="table"}). The following health information was also included: body mass index, smoking status, alcohol use, exercise habits, diabetes complications experienced, prescribing physician, being afraid of needles, HbA~1c~, fasting glucose, treatment satisfaction, and Charlson comorbidity index. The Charlson comorbidity index is calculated by weighting the presence of specific comorbidities based on their association with future mortality and summing the results. Models consisting of respondents with uncontrolled type 2 diabetes did not include HbA~1c~ level and fasting glucose as predictors.

Quality of life and medication adherence outcomes
-------------------------------------------------

The following measures of quality of life (validated scales) were used in this analysis: physical (PCS) and mental (MCS) component summary scores from the Short Form Survey Instrument Version 2 (SF-12v2). The SF-12v2 is a multipurpose generic measure of health status, consisting of 12 questions designed to assess physical functioning, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for the PCS and MCS rely on norm-based scoring, with higher scores indicating better quality of life. The average score is 50.[@b24-ppa-7-1007]

Medication adherence was assessed using the Morisky Medication Adherence Scale (MMAS). The MMAS consists of four yes/no questions that assess the general adherence of using prescribed medication.[@b25-ppa-7-1007] The total score varies from 0 to 4, with lower scores indicating greater adherence; adherence (0) versus nonadherence (1--4) were compared. Medication adherence data was only collected in 2010 and 2011. Therefore, the sample size is smaller compared with the other metrics.

Statistical analyses
--------------------

Bivariate and multivariate analyses were conducted. Bivariate analyses were used to compare data between patients on insulin versus patients on oral bitherapy or tritherapy, and data between patients starting early insulin versus late insulin. Chi-square tests were used for categorical variables and the *t*-test was used for continuous variables to determine differences between groups.

The independent variables were used in multivariable analyses to identify differences between two groups on quality of life outcome measures and adherence after adjusting for differences in demographics and patient characteristics. This was achieved by regression modeling (logistic and multivariable linear regressions). For all statistical tests, the applied comparison-wise significance level was a *P* value \< 0.05.

Results
=======

Determinants of insulin prescription
------------------------------------

### Patients on insulin versus patients on oral bitherapy or tritherapy

The average age of patients on insulin (n = 270) and on oral bitherapy or tritherapy (n = 443) was comparable (59.14 years versus 60.27 years) while 61.48% and 69.98%, respectively, were men (*P* = 0.021). Those on insulin were younger at diagnosis (mean 44.6 years versus 49.5 years, *P* \< 0.0001), and the average duration of type 2 diabetes since diagnosis was longer (14.7 years versus 10.75 years, *P* \< 0.0001). Socioeconomically, they more likely to have less income (\<€20,000/year: 32.59% versus 21.90%, *P* = 0.0021), and were less likely to have a higher level of secondary education (24.44% versus 33.41%, *P* = 0.0096). In terms of clinical characteristics, they were less frequently overweight (31.85% versus 39.95%, *P* = 0.0277), had a higher Charlson comorbidity index (0.6 versus 0.33, *P* = 0.0017), significantly more likelihood of myocardial infarction (*P* = 0.0422), and presented more microvascular and macrovascular complications (*P* \< 0.0001). They were more often poorly controlled (HbA~1c~ \>7%: 32.96% versus 17.61%, *P* \< 0.0001). They were more frequently followed up by a prescribing physician who was not a general practitioner (77.78% versus 24.15%, *P* \< 0.0001) and were more often aware of their HbA~1c~ level (*P* \< 0.0001). Finally, they were significantly more adherent (adherence MMAS = 0: 82.61% versus 72.36%, *P* = 0.0066). We did not observe differences in terms of healthy lifestyle (physical exercise), risk factors (alcohol, smoking), or fear about needles ([Table 3](#t3-ppa-7-1007){ref-type="table"}).

As shown in [Table 4](#t4-ppa-7-1007){ref-type="table"}, a logistic regression was run to assess factors that influence insulin use versus oral bitherapy or tritherapy use. The probability of taking insulin was raised if the patient presented the following factors, in decreasing order: retinopathy or macular edema (odds ratio \[OR\] 3.035, 95% confidence interval \[CI\] 1.317--6.992, *P* = 0.0091) and neuropathic pain (OR 2.095, 95% CI 1.149--3.822, *P* = 0.0159). On the contrary, patients treated by a specialist had a 12 times greater odds of using insulin (OR 0.083, 95% CI 0.054--0.128, *P* \< 0.0001) versus patients followed up by a prescribing general practitioner, and those who had an income ≥€50,000 per annum were less likely to receive insulin (OR 0.26, 95% CI 0.119--0.567, *P* = 0.0007). Finally, older age at diagnosis was associated with less likelihood of being put on insulin (OR 0.974, 95% CI 0.955--0.994, *P* = 0.0117). Overweight and unknown fasting glucose were marginally significant predictors of oral use.

### Factors influencing early initiation of insulin

As shown in [Table 5](#t5-ppa-7-1007){ref-type="table"}, patients were younger in the type 2 diabetes early insulin initiation group (n = 143) than in the type 2 diabetes initiated later with insulin group (n = 124), ie, 56.37 years versus 62.6 years (*P* \< 0.0001) and this was confirmed in the younger age group at initiation of insulin (47.42 years versus 56.86 years, respectively, *P* \< 0.0001). Fewer males initiated insulin early compared with the late insulin initiation group (55.24% versus 68.55% respectively, *P* \< 0.025). Socioeconomically, they had a lower income (\<€20,000 per year: 38.46% versus 26.61%, *P* = 0.0384). In terms of lifestyle, they were more likely to smoke (23.08% versus 10.48%, *P* = 0.0053), and reported less controlled type 2 diabetes (HbA~1c~ \>7%, 25.87% versus 41.94%, *P* \< 0.0057).

As shown in [Table 6](#t6-ppa-7-1007){ref-type="table"}, a logistic regression was run to assess factors that influence early initiation of insulin (≤5 years) versus late initiation using a median split ([Table 5](#t5-ppa-7-1007){ref-type="table"}). Younger age at diagnosis and currently smoking were significant predictors of early insulin initiation (OR 1.031, 95% CI 1.005--1.059, *P* = 0.0196, and OR 2.537, 95% CI 1.165--5.524, *P* = 0.0191, respectively). Inversely, high income (€20,000--€50,000) was a significant predictor of late insulin initiation (OR 0.452, 95% CI 0.239--0.856, *P* = 0.0148). It should be noted that a currently uncontrolled HbA~1c~ level was a marginally significant predictor of late insulin initiation (OR 0.549, 95% CI 0.28--1.076, *P* = 0.0807).

A logistic regression was also run to assess the factors that influence early insulin initiation versus the subgroup of uncontrolled oral bitherapy or tritherapy users. From [Table 6](#t6-ppa-7-1007){ref-type="table"}, we can see that high income was also associated with late insulin initiation, with patients receiving an income of ≥€50,000 per annum having lower odds of being put on insulin early (OR 0.26, 95% CI 0.072--0.94, *P* = 0.0399). It should be noted that the odds of early initiation of insulin therapy prescribed by an endocrinologist or diabetologist were 9.9 greater compared with a primary care physician (OR 0.101, 95% CI 0.05--0.204, *P* \< 0.0001).

Predictors of control of type 2 diabetes
----------------------------------------

As shown in [Table 7](#t7-ppa-7-1007){ref-type="table"}, when comparing controlled patients (all therapies, n = 224) versus uncontrolled (HbA~1c~ \<7%) patients (n = 208), those with controlled diabetes were older at diagnosis (48.16 years versus 45.38 years, *P* = 0.0109), were less often treated with insulin (38.84% versus 49.52%, *P* = 0.0254), had macular edema less often (6.25% versus 14.42%, *P* = 0.0055), or at least one microvascular complication (20.09% versus 33.65%, *P* = 0.0015), were very satisfied with treatment more often (65.18% versus 46.63%, *P* \< 0.0001), and forgot less often to take their medication (15.87% versus 25.00%, *P* = 0.0411).

A logistic regression was run to assess the factors that influence control of HbA~1c~ (all types of treatment, [Table 8](#t8-ppa-7-1007){ref-type="table"}). Three factors were associated with controlled diabetes, ie, patient satisfaction with treatment (OR 2.545, 95% CI 1.556--4.16, *P* = 0.0002), a short duration of diabetes (OR0.96, 95% CI 0.93--0.991, *P* = 0.0108), and greater patient adherence (OR 1.82, 95% CI 1.015--3.251, *P* = 0.0445).

Predictors of adherence to all types of treatment
-------------------------------------------------

Using the MMAS (MMAS = 0), the average age of type 2 diabetes patients adherent to therapy (n = 385) was higher than that of those nonadherent to therapy (n = 121, 60.72 years versus 57.01 years, respectively, *P* = 0.0008, [Table 9](#t9-ppa-7-1007){ref-type="table"}). The adherent patients were older at diagnosis (47.85 years versus 45.28 years, *P* = 0.0209), while the adherent group was also more likely to be female than the nonadherent group (36.88% versus 26.45%, *P* = 0.0282). Socioeconomically, the adherent group was more likely to have an income of €20,000 to \<€50,000 (55.84% versus 43.80%, *P* = 0.0214), as well as being less likely to be employed (23.38% versus 36.36%, *P* = 0.0087), and were more frequently using insulin (39.48% versus 26.45%, *P* = 0.0066). In terms of clinical characteristics, the adherent group was less likely to drink alcohol (*P* = 0.0365), had significantly more myocardial infarction (*P* = 0.0473), and had more macular edema complications (*P* = 0.0005). They were more frequently followed up by an endocrinologist or diabetologist (47.53% versus 34.71%, *P* = 0.0118). We did not see any difference in terms of control of diabetes.

A logistic regression showed two significant factors of adherence, ie, older age (OR 1.04, 95% CI 1.011--1.071, *P* = 0.0075, [Table 10](#t10-ppa-7-1007){ref-type="table"}) and macular edema or diabetic retinopathy (OR 4.282, 95% CI 1.171--15.659, *P* = 0.0279). Conversely, currently drinking alcohol (OR 0.559, 95% CI 0.319--0.982, *P* = 0.0429), and HbA~1c~ \>7% (OR 0.551, 95% CI 0.307--0.989, *P* = 0.0458) were significant predictors of nonadherence.

Insulin did not appear to be a determining factor of adherence when insulin users were compared with all users of oral bitherapy or tritherapy. However, as shown in [Table 10](#t10-ppa-7-1007){ref-type="table"}, logistic regression comparing insulin users with uncontrolled oral bitherapy and tritherapy users (n = 256) showed that insulin users had 3.0 times greater odds of being adherent (OR 2.983, 95% CI 1.37--6.495, *P* = 0.0059), with even greater odds when early insulin users were considered (3.337, 95% CI 1.295--8.595, *P* = 0.0126).

Impact of insulin on quality of life
------------------------------------

Linear regression models were used to assess the impact of insulin, early insulin initiation, and short (≤5 years) insulin duration versus uncontrolled bitherapy and tritherapy users on MCS and PCS scores. [Table 11](#t11-ppa-7-1007){ref-type="table"} summarizes the adjusted means for MCS and PCS. Overall, no significant difference was observed between the two groups on the MCS (44.182 versus 45.832), and PCS (39.611 versus 40.093) scores. However, one must note the significant difference (*P* = 0.0304) on the MCS in the early insulin initiation subgroup, which can be explained by the eventual complications and negative perception of insulin as a last resort treatment. Indeed, there were no significant differences between the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy. As shown in [Figure 1](#f1-ppa-7-1007){ref-type="fig"}, when the presence or absence of complications were considered, whatever the treatment, the presence of complications had a negative impact on both MCS (42.66 versus 47.36, *P* \< 0.0001) and PCS (34.32 versus 43.48, *P* \< 0.0001).

Analysis of MCS and PCS data based on duration of insulin therapy (\<3 years, 3--5 years, 6--10 years, ≥11 years) allowed observation of the stability of quality of life scores on the two dimensions, with the only significant difference on physical health decreasing after 11 years and more of treatment, compared with \<3 years in relation to the appearance of chronic complications ([Figure 2](#f2-ppa-7-1007){ref-type="fig"}).

Also, as post hoc analyses, type 2 diabetes quality of life scores were compared with other disease conditions. [Figure 3](#f3-ppa-7-1007){ref-type="fig"} shows that patients with type 2 diabetes have lower mental health scores (MCS = 45.86) relative to the average person, but higher levels of mental health than people diagnosed with depression, and similar scores relative to patients with metabolic syndrome, allergic rhinitis, or hepatitis C. Patients with type 2 diabetes had lower levels of physical health (PCS = 42.32) relative to the average person and people suffering from allergic rhinitis and depression, but very similar levels of physical health relative to patients with hepatitis C. Also, quite surprisingly, they had higher levels of physical health compared with those having metabolic syndrome.

Discussion
==========

Determinants of insulin prescription
------------------------------------

In this study, factors determining insulin prescription in multivariable analysis consisted of lower age at type 2 diabetes diagnosis, the presence of retinopathy, neuropathic pain, being treated by a specialist, and lower (\<€50,000 per annum) income. Factors determining early insulin prescription in the course of the disease, as compared with late insulin prescription, were of younger age at diagnosis and had a lower income. When the factors determining early insulin prescription in the course of the disease were analyzed as compared with uncontrolled oral therapy, lower income and being treated by a specialist were observed to be significant.

It is not surprising to observe that patients with severe complications are more often treated with insulin; the effect of an early diabetes onset may be explained by the presence of late autoimmune diabetes among the patients in the study, with up to 10% of patients diagnosed with type 2 diabetes found to have anti-glutamic acid decarboxylase antibodies.[@b26-ppa-7-1007] The higher frequency of specialist care in insulin treated patients must be interpreted with caution. It does not mean that general practitioners are reluctant to prescribe insulin. They may refer the patient to the specialist when they appropriately estimate that insulin should be prescribed: incidentally, this may explain why, in one study, clinical inertia concerning insulin prescription was found to be more frequent among general practitioners than among specialists.[@b14-ppa-7-1007]

The independent effect of patients' income observed herein is more original: our data suggest that patients with a lower income are more frequently treated by insulin. While the deleterious effect of social deprivation on patient adherence is known,[@b27-ppa-7-1007] whether low income leads to an increased risk of doctors' clinical inertia is harder to determine. For instance, one study showed that patients of low socioeconomic class had diabetes more often and were able to achieve treatment targets less often, but in fact had indicators of good practice more often, ie, measurement of HbA~1c~, microalbuminuria, eye examination, treatment by insulin in insufficient control of diabetes.[@b28-ppa-7-1007] However, a more recent study did not show evidence of a language barrier effect on intensification of therapy in patients with type 2 diabetes imbalance, but a low level of income was clearly associated with less treatment intensification.[@b29-ppa-7-1007]

Predictors of control of diabetes
---------------------------------

In the bivariate analysis, we observed classical determinants of diabetes control, such as diabetes duration, adherence to therapy (the effect of adherence on metabolic control, hypercholesterolemia, and hypertension is also well substantiated),[@b30-ppa-7-1007]--[@b33-ppa-7-1007] and, as expected, we observed an association of good control with less frequency of diabetic complications.

The strong effect of satisfaction towards treatment is more puzzling: not the fact that controlled patients are more frequently satisfied by their treatment, which seems to hold true. But the fact that in the multivariable analysis this determinant had by far the strongest link with diabetes control, suggesting that other factors (eg, dosage, number of required treatments per day) could be influencing this particular variable.

Predictors of patient adherence
-------------------------------

This study confirms the known determinants of adherence observed in the multivariable analysis, ie, older age,[@b34-ppa-7-1007]--[@b37-ppa-7-1007] abstinence from drinking,[@b38-ppa-7-1007] metabolic control,[@b30-ppa-7-1007],[@b31-ppa-7-1007],[@b39-ppa-7-1007] and the presence of complications.[@b37-ppa-7-1007] Surprisingly, we did not observe any association between nonsmoking and adherence, which was shown in some studies.[@b40-ppa-7-1007]--[@b43-ppa-7-1007] In bivariate analysis, we observed that adherent respondents were less likely to be employed. This was also observed in the recent French ENTRED (Medication Adherence in Type 2 Diabetes) study.[@b37-ppa-7-1007] In our study, adherent patients reported lower income status, while in the ENTRED study,[@b37-ppa-7-1007] financial difficulties were associated with a low adherence rate, as in a Swedish study.[@b27-ppa-7-1007] The fact that, in our study, lower income was associated with good adherence is consistent with a Canadian study.[@b44-ppa-7-1007] The fact that the same findings were observed in France, where diabetic drugs are paid by the social security program, suggests that this effect may not be due to what was observed in Canada (the effect of copayment).

In our study, insulin adherence was better in patients treated with insulin than in those treated with oral antidiabetic medication, especially in the case of early insulin prescription. Indeed, insulin users had 3.0 times greater odds of being adherent compared with uncontrolled oral bitherapy or tritherapy users (OR 2.983, *P* = 0.0059). Interestingly, the fact that adherence may be better with injections was proposed as an argument to favor injectable rather than oral penicillin in children with impaired splenic function,[@b45-ppa-7-1007] and it is also a concern when considering adherence to cancer therapy.[@b46-ppa-7-1007] This better adherence to injectable therapy, observed in our study, is in contradiction with the general concern of physicians concerning patient adherence as a cause of psychological insulin resistance.[@b47-ppa-7-1007]

Effect of treatment with insulin on quality of life
---------------------------------------------------

Overall, no significant difference was observed between insulin users and uncontrolled bitherapy or tritherapy users concerning MCS and PCS scores. Quality of life, both physical and mental, was therefore not altered compared with that in patients uncontrolled on bitherapy or tritherapy. Physical health scores decreased after 11 years of diabetes therapy, possibly an effect of the appearance of chronic complications. The lower MCS score in the early insulin initiation subgroup may also be explained by the eventual presence of complications, which were well analyzed in this study ([Figure 1](#f1-ppa-7-1007){ref-type="fig"}). Indeed, there were no significant differences for the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy.

In this context of quality of life, reflecting the burden of the disease, it was interesting to compare the European data concerning type 2 diabetes with those of other high-prevalence chronic diseases. For this comparison, previous European NHWS studies were prioritized, because the methodology and measures were the same, thus providing the most suitable and relevant basis for comparison with diabetes in the current study. Comparison of scores ([Figure 3](#f3-ppa-7-1007){ref-type="fig"}) shows that the MCS and PCS scores for patients with type 2 diabetes are comparable across other conditions, and patients with type 2 diabetes have relative lower scores than the general population.

Although this study has some weak points, many of the findings are consistent with those reported in the literature. The first limitation is the relatively small number of patients as compared with other studies addressing specific issues, such as patient adherence based on refill evaluation, allowing analysis of much larger populations. Thus, the small sample sizes in the current study precluded the ability to conduct multivariable analyses for specific delays or duration of treatment, or to generalize broadly from the current data. Future research should adjust for possible confounds with larger samples and multivariable analysis.

Secondly, the Internet survey methodology may have introduced bias, explaining for instance the unexpected high male to female ratio observed in this study. The Internet survey was a real limitation in France in 2008, with lower Internet penetration in the female population explaining the overestimation of males in the diabetic population, as in 2010 this bias was less important with a rate of 59% of males much closer to the normal rate of 54% in type 2 diabetes.[@b37-ppa-7-1007] Also, due to the self-report nature of the current study, no verification of diagnoses, treatment, fasting glucose, HbA~1c~ level or disease complications was made.

Third, cross-sectional data provide a one-time snapshot of the relationships between study variables. They can suggest directions for further research, but definite claims cannot be made regarding causal relationships among domains (eg, earlier insulin initiation and quality of life or adherence). However, the relevance of this data is strong because of the comparable methodology; 3 years of data can be pulled and a larger sample size is achievable, the patients reported are looking at many different measures using validated scales (the MMAS and SF-12v2) and even more are looking at treatment satisfaction, all these dimensions that can only have been caught from the patient perspective.

Conclusion
==========

With these limitations in mind, the current study contributes to the growing literature documenting the burden and health effects associated with insulin treatment. There may be a rationale for prescribing insulin earlier than what is done with the current treatment paradigm.[@b5-ppa-7-1007] Recently, the effect of introducing insulin early in the course of the disease was reported in the ORIGIN (Outcome Reduction with Initial Glargine Intervention insuliN glargine therapy) study.[@b48-ppa-7-1007] The effect on prevention of mortality was neutral in this study. However, early insulin initiation was shown to be safe, leading to a modest increase in body weight and in the rate of severe hypoglycemia, and was reassuring concerning the risk of cancer. There was a reduction in diabetes incidence in individuals having only prediabetes at entry to the study. Thus, given the potential impact of prescribing insulin earlier, the current paper provides important information regarding the experience of insulin users in France. Finally, the main finding of our study was an unexpected improvement in adherence among insulin-treated patients, and the absence of a deleterious effect on quality of life in patients with no complications. This may represent an argument to fight against psychological insulin resistance.
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###### 

Sample sizes

  Groups (deduped)[\*](#tfn1-ppa-7-1007){ref-type="table-fn"}                               Sample size (n)
  ----------------------------------------------------------------------------------------- -----------------
  All oral bitherapy or tritherapy users                                                    443
  Uncontrolled[\*\*](#tfn2-ppa-7-1007){ref-type="table-fn"} bitherapy or tritherapy users   105
   without any complications                                                                360
  All insulin users                                                                         270
   With:                                                                                    
   Early insulin initiation (5 years or less)                                               143
   Early insulin initiation (5 years or less) without any complication\^                    77
   Short duration of insulin (5 years or less)                                              141
   Short duration of insulin (5 years or less) without any complication\^                   94

**Notes:**

Users of glucagon-like peptide-1 were excluded from this analysis due to their small sample size (n = 46)

uncontrolled users were defined as having an HbA~1c~ \>7% or, if they were missing their HbA~1c~ level their fasting plasma glucose was \>130 mg/dL; \^a complication was defined as reporting having myocardial infarction, stroke, transient ischemic attack, diabetic retinopathy, diabetic peripheral neuropathy, kidney damage, end organ damage (only collected in 2010 and 2011), or foot ulcer.

###### 

Definition of covariates

  Parameter                                           Reference
  --------------------------------------------------- -----------------------------------------------------------------
  Age/age at diagnosis                                --
  Duration of type 2 diabetes                         
  Sex                                                 Male
  College degree +                                    Less than college degree
  Income                                              
   €20,000 to \<€50,000                               \<€20,000
   ≥€50,000                                           
   ≥Decline to answer                                 
  Employed full-time/part-time/self-employed          Unemployed
  Currently drinking alcohol                          No current alcohol use
  Currently smoking                                   Not a current smoker
  Currently exercising                                No current exercise
  Body mass index                                     
   Overweight                                         Normal/underweight
   Obese                                              
   Declined                                           
  Charlson comorbidity index                          --
  Complications experienced                           
   Macular edema or diabetic retinopathy              Not experienced
   Neuropathic pain                                   
   Kidney disease                                     
   Foot or leg ulcer                                  
  Prescribing physician, general practitioner         Specialist
  Strongly agree/agree with being afraid of needles   Neutral/disagree/strongly disagree with being afraid of needles
  HbA~1c~                                             ≤7%
   \>7%                                               
   Unknown                                            
  Fasting glucose                                     
   ≥130 mg/dL                                         ≤130 mg/dL
   Unknown                                            
  Very/extremely satisfied with diabetes treatment    Less satisfaction with diabetes treatment

**Note**: Models representing uncontrolled individuals did not include HbA~1c~ levels or fasting glucose as covariates.

###### 

Analyzed population: all insulin users versus all users of bitherapy or tritherapy

                                                                                   All insulin users n = 270   All bi- or tritherapy users n = 443   *P*-value            
  -------------------------------------------------------------------------------- --------------------------- ------------------------------------- ----------- -------- ----------
  Age (mean, SD)                                                                   59.14                       10.86                                 60.27       9.32     0.1554
   Age at diagnosis                                                                44.6                        11.95                                 49.53       10.39    \<0.0001
   Age at insulin initiation                                                       51.61                       13.03                                 --          --       N/A
   Years diagnosed                                                                 14.66                       9.88                                  10.75       7.61     \<0.0001
  Sex                                                                                                                                                                     
   Male                                                                            166                         61.48%                                310         69.98%   0.0213
   Female                                                                          104                         38.52%                                133         30.02%   0.0213
  Currently employed                                                               76                          28.15%                                121         27.31%   0.8096
  Household income                                                                                                                                                        
   \<20,000€                                                                       88                          32.59%                                97          21.90%   0.0021
   20,000€ to \<50,000€                                                            138                         51.11%                                233         52.60%   0.7006
   50,000€ or more                                                                 22                          8.15%                                 65          14.67%   0.0061
   Decline to answer                                                               22                          8.15%                                 48          10.84%   0.2281
  College education                                                                66                          24.44%                                148         33.41%   0.0096
  BMI                                                                                                                                                                     
   Underweight                                                                     0                           0.00%                                 1           0.23%    N/A
   Normal weight                                                                   40                          14.81%                                45          10.16%   0.0735
   Overweight                                                                      86                          31.85%                                177         39.95%   0.0277
   Obese                                                                           135                         50.00%                                209         47.18%   0.4651
   Decline to answer                                                               9                           3.33%                                 11          2.48%    0.5197
  Health behaviors                                                                                                                                                        
   Currently drink                                                                 190                         70.37%                                336         75.85%   0.1126
   Currently smoke                                                                 47                          17.41%                                75          16.93%   0.8701
   Regularly exercise                                                              141                         52.22%                                238         53.72%   0.697
  Charlson comorbidity index (mean, SD)                                            0.6                         1.33                                  0.33        0.69     0.0017
  Comorbidities                                                                                                                                                           
   Depression                                                                      36                          13.33%                                50          11.29%   0.4242
   Myocardial infarction                                                           23                          8.52%                                 20          4.51%    0.0422
   Stroke                                                                          12                          4.44%                                 10          2.26%    0.1294
   TIA                                                                             4                           1.48%                                 2           0.45%    0.1995
   Congestive heart failure                                                        8                           2.96%                                 7           1.58%    0.246
   Hypertension                                                                    111                         41.11%                                205         46.28%   0.1771
   Angina                                                                          27                          10.00%                                50          11.29%   0.5869
   Arrhythmia                                                                      13                          4.81%                                 31          7.00%    0.2208
  Prescribing physician                                                                                                                                                   
   PCP                                                                             53                          19.63%                                334         75.40%   \<0.0001
   Endocrinologist/diabetologist                                                   210                         77.78%                                107         24.15%   \<0.0001
   Nurse practitioner/physician assistant                                          0                           0.00%                                 0           0.00%    N/A
   Other                                                                           7                           2.59%                                 2           0.45%    0.0361
  Agree/strongly agree to being afraid of needles                                  24                          8.89%                                 47          10.61%   0.4485
  Microvascular complications                                                                                                                                             
   Macular edema                                                                   43                          15.93%                                14          3.16%    \<0.0001
   Neuropathic pain                                                                53                          19.63%                                33          7.45%    \<0.0001
   Kidney damage                                                                   28                          10.37%                                11          2.48%    \<0001
   End organ damage (2010, 2011 only)                                              14                          7.61%                                 5           1.55%    0.0038
   Foot ulcer                                                                      14                          5.19%                                 16          3.61%    0.3305
  At least one microvascular complication                                          104                         38.52%                                64          14.45%   \<0.0001
  At least one complication (TIA, stroke, HA or microvascular complication)        119                         44.07%                                83          18.74%   \<0.0001
  HbA~1c~ (%)                                                                                                                                                             
   HbA~1c~ \>7                                                                     89                          32.96%                                78          17.61%   \<0.0001
   HbA~1c~ (missing)                                                               94                          34.81%                                228         51.47%   \<0.0001
  Fasting glucose (mg/dl)                                                                                                                                                 
   Fasting glucose \>130                                                           42                          15.56%                                45          10.16%   0.0409
   Fasting glucose (missing)                                                       152                         56.30%                                311         70.20%   0.0002
  Satisfaction with treatment                                                                                                                                             
   Very/extremely satisfied with treatment                                         149                         55.60%                                227         51.24%   0.2592
   Very/extremely dissatisfied with treatment                                      40                          14.93%                                51          11.51%   0.1991
  Morisky adherence[\*](#tfn4-ppa-7-1007){ref-type="table-fn"} (2010, 2011 only)                                                                                          
   Compliant (MMAs = 0)                                                            152                         82.61%                                233         72.36%   0.0066
   Forget to take medication                                                       25                          13.59%                                80          24.84%   0.0014
   Careless about medication                                                       12                          6.52%                                 36          11.18%   0.0667
   Stop when feeling better                                                        1                           0.54%                                 5           1.55%    0.2508
   Stop when feeling worse                                                         5                           2.72%                                 16          4.97%    0.1876

**Notes:**

Assessed using the MMAS. The MMAS includes four items ("do you ever forget to take your medicine?"; "are you careless at times about taking your medicine?"; "when you feel better do you sometimes stop taking your medicine?"; and "sometimes if you feel worse when you take your medicine, do you stop taking it?"). All items have a dichotomous yes/no response scale and are summed to form a total score (which varies from 0 to 4, with lower scores indicating greater adherence).

**Abbreviations:** BMI, body mass index; MMAS, Morisky Medication Adherence Scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

###### 

Statistically significant factors influencing prescription of insulin: insulin users versus bitherapy or tritherapy users (n = 705)

  Parameter                               Estimate   OR      95% LCL for OR   95% UCL for OR   SE       Chi-square   *P*-value
  --------------------------------------- ---------- ------- ---------------- ---------------- -------- ------------ -----------
  Age at diagnosis                        −0.026     0.974   0.955            0.994            0.0103   6.3489       0.0117
  Income: ≥€50,000                        −1.349     0.26    0.119            0.567            0.3987   11.439       0.0007
  Income: declined to answer              −0.831     0.436   0.201            0.944            0.3949   4.4294       0.0353
  Macular edema or diabetic retinopathy   1.1102     3.035   1.317            6.992            0.4258   6.7983       0.0091
  Neuropathic pain                        0.7397     2.095   1.149            3.822            0.3067   5.8187       0.0159
  Prescribing physician: GP               −2.486     0.083   0.054            0.128            0.2201   127.62       \<0.0001

**Abbreviations:** GP, general practitioner; OR, odds ratio; SE, standard error; LCL, lower confidence limit; UCL, upper confidence limit.

###### 

Analyzed population: early versus late insulin initiation

                                                                              Early insulin initiation (5 years or less) n = 143   Late insulin initiation (6 years or more) n = 124   *P*-value            
  --------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ----------- -------- ----------
  Age (mean, SD)                                                              56.37                                                11.09                                               62.6        8.81     \<0.0001
   Age at diagnosis                                                           45.74                                                13.52                                               43.29       9.73     0.0875
   Age at insulin initiation                                                  47.42                                                13.95                                               56.86       9.41     \<0.0001
  Sex                                                                                                                                                                                                       
   Male                                                                       79                                                   55.24%                                              85          68.55%   0.025
   Female                                                                     64                                                   44.76%                                              39          31.45%   0.025
  Currently employed                                                          44                                                   30.77%                                              30          24.19%   0.2295
  Household income                                                                                                                                                                                          
   \<20,000€                                                                  55                                                   38.46%                                              33          26.61%   0.0384
   20,000€ to \<50,000€                                                       62                                                   43.36%                                              73          58.87%   0.0112
   50,000€ or more                                                            11                                                   7.69%                                               11          8.87%    0.7288
   Decline to answer                                                          15                                                   10.49%                                              7           5.65%    0.1435
  College education                                                           37                                                   25.87%                                              28          22.58%   0.5314
  BMI                                                                                                                                                                                                       
   Underweight                                                                0                                                    0.00%                                               0           0.00%    N/A
   Normal weight                                                              22                                                   15.38%                                              15          12.10%   0.4358
   Overweight                                                                 41                                                   28.67%                                              45          36.29%   0.1864
   Obese                                                                      74                                                   51.75%                                              61          49.19%   0.6779
   Decline to answer                                                          6                                                    4.20%                                               3           2.42%    0.4149
  Health behaviors                                                                                                                                                                                          
   Currently drink                                                            96                                                   67.13%                                              92          74.19%   0.2058
   Currently smoke                                                            33                                                   23.08%                                              13          10.48%   0.0053
   Regularly exercise                                                         72                                                   50.35%                                              67          54.03%   0.5489
  Charlson comorbidity index (mean, SD)                                       0.59                                                 1.33                                                0.62        1.33     0.8712
  Comorbidities                                                                                                                                                                                             
   Depression                                                                 22                                                   15.38%                                              13          10.48%   0.232
   Myocardial infarction                                                      13                                                   9.09%                                               10          8.06%    0.7654
   Stroke                                                                     6                                                    4.20%                                               6           4.84%    0.8018
   TIA                                                                        1                                                    0.70%                                               3           2.42%    0.2677
   Congestive heart failure                                                   4                                                    2.80%                                               4           3.23%    0.8389
   Hypertension                                                               64                                                   44.76%                                              46          37.10%   0.2045
   Angina                                                                     18                                                   12.59%                                              9           7.26%    0.1432
   Arrhythmia                                                                 4                                                    2.80%                                               9           7.26%    0.1013
  Prescribing physician                                                                                                                                                                                     
   PCP                                                                        27                                                   18.88%                                              26          20.97%   0.6716
   Endocrinologist/diabetologist                                              113                                                  79.02%                                              94          75.81%   0.5327
   Nurse practitioner/physician assistant                                     0                                                    0.00%                                               0           0.00%    N/A
   Other                                                                      3                                                    2.10%                                               4           3.23%    0.5718
  Agree/strongly agree to being afraid of needles                             14                                                   9.79%                                               10          8.06%    0.6217
  Microvascular complications                                                                                                                                                                               
   Macular edema                                                              21                                                   14.69%                                              22          17.74%   0.5013
   Neuropathic pain                                                           31                                                   21.68%                                              22          17.74%   0.4198
   Kidney damage                                                              16                                                   11.19%                                              12          9.68%    0.6871
   End organ damage (2010, 2011 only)                                         7                                                    7.29%                                               7           8.05%    0.8489
   Foot ulcer                                                                 9                                                    6.29%                                               5           4.03%    0.4025
  At least one microvascular complication                                     58                                                   40.56%                                              46          37.10%   0.5633
  At least one complication (TIA, stroke,HA, or microvascular complication)   66                                                   46.15%                                              53          42.74%   0.5766
  HbA~1c~(%)                                                                                                                                                                                                
   HbA~1c~ \>7                                                                37                                                   25.87%                                              52          41.94%   0.0057
   HbA~1c~ (missing)                                                          59                                                   41.26%                                              35          28.23%   0.025
  Fasting glucose (mg/dl)                                                                                                                                                                                   
   Fasting glucose \>130                                                      25                                                   17.48%                                              17          13.71%   0.3961
   Fasting glucose (missing)                                                  83                                                   58.04%                                              67          54.03%   0.5115
  Satisfaction with treatment                                                                                                                                                                               
   Very/extremely satisfied with treatment                                    80                                                   56.74%                                              66          53.23%   0.5675
   Very/extremely dissatisfied with treatment                                 20                                                   14.18%                                              20          16.13%   0.661
  Morisky adherence                                                                                                                                                                                         
   Compliant (MMAS = 0)                                                       82                                                   85.42%                                              69          79.31%   0.2819
   Forget to take medication                                                  11                                                   11.46%                                              14          16.09%   0.3668
   Careless about medication                                                  8                                                    8.33%                                               4           4.60%    0.3029
   Stop when feeling better                                                   0                                                    0.00%                                               1           1.15%    N/A
   Stop when feeling worse                                                    3                                                    3.13%                                               2           2.30%    0.7312

**Abbreviations:** BMI, body mass index; MMAS, Morisky Medication Adherence Scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

###### 

Statistically significant factors influencing early insulin initiation

  Parameter                                                                                        Estimate   OR      95% LCL for OR 95% UCL for OR   SE      Chi-square   *P*-value   
  ------------------------------------------------------------------------------------------------ ---------- ------- ------------------------------- ------- ------------ ----------- ----------
  **Influencing early insulin initiation versus late initiation (median split = 5, n = 265)**                                                                                          
  Age at diagnosis                                                                                 0.0309     1.031   1.005                           1.059   0.0132       5.4509      0.0196
  Income: €20,000 to\<€50,000                                                                      −0.795     0.452   0.239                           0.856   0.3259       5.944       0.0148
  Currently smoking                                                                                0.9308     2.537   1.165                           5.524   0.3971       5.496       0.0191
  HbA~1c~ \>7%                                                                                     −0.6       0.549   0.28                            1.076   0.3436       3.0503      0.0807
  **Influencing early insulin initiation versus uncontrolled bitherapy or tritherapy (n = 245)**                                                                                       
  Income: €20,000 to \<€50,000                                                                     −0.825     0.438   0.195                           0.985   0.4133       3.9838      0.0459
  Income: ≥€50,000                                                                                 −1.347     0.26    0.072                           0.94    0.6556       4.2236      0.0399
  Prescribing physician: GP                                                                        −2.292     0.101   0.05                            0.204   0.3577       41.059      \<0.0001

**Abbreviations:** OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error; GP, general practitioner.

###### 

Analyzed population: all controlled insulin/bitherapy or tritherapy users versus uncontrolled insulin/bitherapy or tritherapy users (excluding missing HbA~1c~ level)

                                                                               All controlled insulin/bi- or tritherapy users n = 224   Uncontrolled insulin/bi- or tritherapy users (excluding missing HbA~1c~ level) n = 208   *P*-value            
  ---------------------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------- -------- ----------
  Age (mean, SD)                                                               60.93                                                    10.5                                                                                     59.54       9.16     0.1413
   Age at diagnosis                                                            48.16                                                    11.57                                                                                    45.38       10.92    0.0109
   Age at insulin initiation (only insulin users)                              50.72                                                    15.23                                                                                    51.17       12.03    0.8273
   Years diagnosed                                                             12.95                                                    9.48                                                                                     14.09       8.81     0.2009
  Therapy                                                                                                                                                                                                                                             
   Bi/tri oral therapy users                                                   137                                                      61.16%                                                                                   105         50.48%   0.0254
   Insulin users                                                               87                                                       38.84%                                                                                   103         49.52%   0.0254
  Sex                                                                                                                                                                                                                                                 
   Male                                                                        147                                                      65.63%                                                                                   141         67.79%   0.634
   Female                                                                      77                                                       34.38%                                                                                   67          32.21%   0.634
  Currently employed                                                           51                                                       22.77%                                                                                   64          30.77%   0.0609
  Household income                                                                                                                                                                                                                                    
   \<20,000€                                                                   56                                                       25.00%                                                                                   50          24.04%   0.8167
   20,000€ to \<50,000€                                                        119                                                      53.13%                                                                                   116         55.77%   0.5819
   50,000€ or more                                                             36                                                       16.07%                                                                                   25          12.02%   0.2252
   Decline to answer                                                           13                                                       5.80%                                                                                    17          8.17%    0.3364
  College education                                                            77                                                       34.38%                                                                                   66          31.73%   0.5598
  BMI                                                                                                                                                                                                                                                 
   Underweight                                                                 1                                                        0.45%                                                                                    0           0.00%    N/A
   Normal weight                                                               23                                                       10.27%                                                                                   28          13.46%   0.3066
   Overweight                                                                  90                                                       40.18%                                                                                   80          38.46%   0.7155
   Obese                                                                       105                                                      46.88%                                                                                   96          46.15%   0.8808
   Decline to answer                                                           5                                                        2.23%                                                                                    4           1.92%    0.822
  Health behaviors                                                                                                                                                                                                                                    
   Currently drink                                                             175                                                      78.13%                                                                                   152         73.08%   0.2232
   Currently smoke                                                             29                                                       12.95%                                                                                   36          17.31%   0.2076
   Regularly exercise                                                          137                                                      61.16%                                                                                   109         52.40%   0.0665
  Charlson comorbidity index (mean, SD)                                        0.38                                                     0.91                                                                                     0.44        0.87     0.4965
  Comorbidities                                                                                                                                                                                                                                       
   Depression                                                                  25                                                       11.16%                                                                                   25          12.02%   0.7811
   Myocardial infarction                                                       15                                                       6.70%                                                                                    10          4.81%    0.3988
   Stroke                                                                      6                                                        2.68%                                                                                    10          4.81%    0.2469
   TIA                                                                         2                                                        0.89%                                                                                    4           1.92%    0.3676
   Congestive heart failure                                                    3                                                        1.34%                                                                                    7           3.37%    0.1686
   Hypertension                                                                106                                                      47.32%                                                                                   95          45.67%   0.7319
   Angina                                                                      28                                                       12.50%                                                                                   17          8.17%    0.1388
   Arrhythmia                                                                  11                                                       4.91%                                                                                    18          8.65%    0.124
  Prescribing physician                                                                                                                                                                                                                               
   PCP                                                                         104                                                      46.43%                                                                                   95          45.67%   0.8751
   Endocrinologist/diabetologist                                               117                                                      52.23%                                                                                   112         53.85%   0.7374
   Nurse practitioner/physician assistant                                      0                                                        0.00%                                                                                    0           0.00%    N/A
  Other                                                                        3                                                        1.34%                                                                                    1           0.48%    0.3442
  Agree/strongly agree to being afraid of needles                              21                                                       9.38%                                                                                    22          10.58%   0.6778
  Microvascular complications                                                                                                                                                                                                                         
   Macular edema                                                               14                                                       6.25%                                                                                    30          14.42%   0.0055
   Neuropathic pain                                                            26                                                       11.61%                                                                                   33          15.87%   0.2003
   Kidney damage                                                               10                                                       4.46%                                                                                    16          7.69%    0.1628
   End organ damage (2010, 2011 only)                                          7                                                        3.70%                                                                                    5           3.38%    0.8725
   Foot ulcer                                                                  6                                                        2.68%                                                                                    11          5.29%    0.1685
  At least one microvascular complication                                      45                                                       20.09%                                                                                   70          33.65%   0.0015
  At least one complication (TIA, stroke, HA, or microvascular complication)   54                                                       24.11%                                                                                   81          38.94%   0.0009
  HbA~1c~ (%)                                                                                                                                                                                                                                         
   HbA~1c~ \>7                                                                 0                                                        0.00%                                                                                    167         80.29%   N/A
   HbA~1c~ (missing)                                                           0                                                        0.00%                                                                                    41          19.71%   N/A
  Fasting glucose (mg/dl)                                                                                                                                                                                                                             
   Fasting glucose \>130                                                       19                                                       8.48%                                                                                    68          32.69%   \<0.0001
   Fasting glucose (missing)                                                   130                                                      58.04%                                                                                   86          41.35%   0.0005
  Satisfaction with treatment                                                                                                                                                                                                                         
   Very/extremely satisfied with treatment                                     146                                                      65.18%                                                                                   97          46.63%   \<0.0001
   Very/extremely dissatisfied with treatment                                  31                                                       13.84%                                                                                   24          11.54%   0.4728
  Morisky adherence (2010, 2011 only)                                                                                                                                                                                                                 
   Compliant (MMAS = 0)                                                        154                                                      81.48%                                                                                   108         72.97%   0.0667
   Forget to take medication                                                   30                                                       15.87%                                                                                   37          25.00%   0.0411
   Careless about medication                                                   14                                                       7.41%                                                                                    12          8.11%    0.8123
   Stop when feeling better                                                    2                                                        1.06%                                                                                    0           0.00%    N/A
   Stop when feeling worse                                                     4                                                        2.12%                                                                                    5           3.38%    0.4885

**Abbreviations:** BMI, body mass index; MMAS, Morisky Medication Adherence scale; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

###### 

Statistically significant factors influencing control of diabetes: all controlled insulin/bitherapy or tritherapy users versus uncontrolled insulin/bitherapy or tritherapy users (n = 336)

  Parameter                                 Estimate   OR      95% LCL for OR   95% UCL for OR   SE       Chi-square   *P*-value
  ----------------------------------------- ---------- ------- ---------------- ---------------- -------- ------------ -----------
  Duration of type 2 diabetes               −0.041     0.96    0.93             0.991            0.0161   6.4939       0.0108
  Compliant                                 0.5967     1.816   1.015            3.251            0.297    4.0362       0.0445
  Very/extremely satisfied with treatment   0.934      2.545   1.556            4.16             0.2508   13.8687      0.0002

**Note:** Excludes respondents who did not know their HbA~1c~ level.

**Abbreviations:** OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error.

###### 

Analyzed population: all adherent insulin/bitherapy or tritherapy users versus all nonadherent insulin/bitherapy or tritherapy users

                                                                               Non-compliant -- total treatment insulin/bi- or tritherapy users n = 121   Compliant -- total treatment insulin/bi- or tritherapy users n = 385   *P*-value            
  ---------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------- -------- --------
  Age (mean, SD)                                                               57.01                                                                      10.75                                                                  60.72       9.27     0.0008
   Age at diagnosis                                                            45.28                                                                      10.58                                                                  47.85       10.68    0.0209
   Age at insulin initiation (only insulin users)                              50.47                                                                      11.82                                                                  52.51       12.02    0.3813
   Years diagnosed                                                             11.73                                                                      8.2                                                                    12.97       8.82     0.1564
  Therapy                                                                                                                                                                                                                                             
   Bi/tri oral therapy users                                                   89                                                                         73.55%                                                                 233         60.52%   0.0066
   Insulin users                                                               32                                                                         26.45%                                                                 152         39.48%   0.0066
  Sex                                                                                                                                                                                                                                                 
   Male                                                                        89                                                                         73.55%                                                                 243         63.12%   0.0282
   Female                                                                      32                                                                         26.45%                                                                 142         36.88%   0.0282
  Currently employed                                                           44                                                                         36.36%                                                                 90          23.38%   0.0087
  Household income                                                                                                                                                                                                                                    
   \<20,000€                                                                   34                                                                         28.10%                                                                 99          25.71%   0.6091
   20,000€ to \<50,000€                                                        53                                                                         43.80%                                                                 215         55.84%   0.0214
   50,000€ or more                                                             19                                                                         15.70%                                                                 36          9.35%    0.082
   Decline to answer                                                           15                                                                         12.40%                                                                 35          9.09%    0.3232
  College education                                                            47                                                                         38.84%                                                                 141         36.62%   0.6619
  BMI                                                                                                                                                                                                                                                 
   Underweight                                                                 0                                                                          0.00%                                                                  1           0.26%    N/A
   Normal weight                                                               14                                                                         11.57%                                                                 38          9.87%    0.6051
   Overweight                                                                  41                                                                         33.88%                                                                 145         37.66%   0.4475
   Obese                                                                       64                                                                         52.89%                                                                 186         48.31%   0.3801
   Decline to answer                                                           2                                                                          1.65%                                                                  15          3.90%    0.1428
  Health behaviors                                                                                                                                                                                                                                    
   Currently drink                                                             96                                                                         79.34%                                                                 270         70.13%   0.0365
   Currently smoke                                                             24                                                                         19.83%                                                                 60          15.58%   0.298
   Regularly exercise                                                          59                                                                         48.76%                                                                 202         52.47%   0.4777
  Charlson comorbidity index (mean, SD)                                        0.29                                                                       0.72                                                                   0.36        0.72     0.3776
  Comorbidities                                                                                                                                                                                                                                       
   Depression                                                                  10                                                                         8.26%                                                                  50          12.99%   0.1218
   Myocardial infarction                                                       3                                                                          2.48%                                                                  24          6.23%    0.0473
   stroke                                                                      3                                                                          2.48%                                                                  15          3.90%    0.4124
   TIA                                                                         2                                                                          1.65%                                                                  3           0.78%    0.4831
   Congestive heart failure                                                    0                                                                          0.00%                                                                  10          2.60%    N/A
   Hypertension                                                                58                                                                         47.93%                                                                 164         42.60%   0.3059
   Angina                                                                      21                                                                         17.36%                                                                 44          11.43%   0.1217
   Arrhythmia                                                                  4                                                                          3.31%                                                                  28          7.27%    0.0606
  Prescribing physician                                                                                                                                                                                                                               
   PCP                                                                         79                                                                         65.29%                                                                 199         51.69%   0.0077
   Endocrinologist/diabetologist                                               42                                                                         34.71%                                                                 183         47.53%   0.0118
   Nurse practitioner/physician assistant                                      0                                                                          0.00%                                                                  0           0.00%    N/A
   Other                                                                       0                                                                          0.00%                                                                  3           0.78%    N/A
  Agree/strongly agree to being afraid of needles                              16                                                                         13.22%                                                                 34          8.83%    0.1989
  Microvascular complications                                                                                                                                                                                                                         
   Macular edema                                                               3                                                                          2.48%                                                                  38          9.87%    0.0005
   Neuropathic pain                                                            16                                                                         13.22%                                                                 45          11.69%   0.6605
   Kidney damage                                                               4                                                                          3.31%                                                                  19          4.94%    0.4083
   End organ damage (2010, 2011 only)                                          4                                                                          3.31%                                                                  15          3.90%    0.7566
   Foot ulcer                                                                  4                                                                          3.31%                                                                  15          3.90%    0.7566
  At least one microvascular complication                                      25                                                                         20.66%                                                                 93          24.16%   0.4154
  At least one complication (TIA, stroke, HA, or microvascular complication)   30                                                                         24.79%                                                                 110         28.57%   0.4078
  HbA~1c~ (%)                                                                                                                                                                                                                                         
   HbA~1c~ \>7                                                                 39                                                                         32.23%                                                                 104         27.01%   0.2802
   HbA~1c~ (missing)                                                           47                                                                         38.84%                                                                 127         32.99%   0.247
  Fasting glucose (mg/dl)                                                                                                                                                                                                                             
   Fasting glucose \>130                                                       5                                                                          4.13%                                                                  15          3.90%    0.9089
   Fasting glucose (missing)                                                   80                                                                         66.12%                                                                 243         63.12%   0.546
  Satisfaction with treatment                                                                                                                                                                                                                         
   Very/extremely satisfied with treatment                                     56                                                                         46.67%                                                                 218         56.77%   0.0545
   Very/extremely dissatisfied with treatment                                  13                                                                         10.83%                                                                 55          14.32%   0.2998

**Abbreviations:** BMI, body mass index; SD, standard deviation; HA, heart attack; TIA, transient ischemic attack; PCP, primary care physician.

###### 

Statistically significant factors influencing adherence to diabetes medication: adherent versus nonadherent users

  Parameter                                                                               Estimate   OR      95% LCL for OR   95% UCL for OR   SE       Chi-square   *P*-value
  --------------------------------------------------------------------------------------- ---------- ------- ---------------- ---------------- -------- ------------ -----------
  **All insulin/bitherapy or tritherapy users (n = 503)**                                                                                                            
  Age at diagnosis                                                                        0.0396     1.04    1.011            1.071            0.0148   7.1376       0.0075
  Currently drinking alcohol                                                              −0.5813    0.559   0.319            0.982            0.2871   4.0984       0.0429
  Macular edema or diabetic retinopathy                                                   1.4543     4.282   1.171            15.659           0.6616   4.8316       0.0279
  HbA~1c~ \>7%                                                                            −0.5954    0.551   0.307            0.989            0.2981   3.9884       0.0458
  **All insulin users and uncontrolled bitherapy or tritherapy users (n = 256)**                                                                                     
  All insulin versus uncontrolled bitherapy or tritherapy                                 1.0931     2.983   1.37             6.495            0.3969   7.5828       0.0059
  Macular edema or diabetic retinopathy                                                   1.8705     6.492   1.301            32.381           0.8199   5.2042       0.0225
  Very/extremely satisfied with treatment                                                 0.7141     2.042   1.043            3.998            0.3427   4.3427       0.0372
  **Early insulin initiation and uncontrolled bitherapy or tritherapy users (n = 169)**                                                                              
  Early insulin versus uncontrolled bitherapy or tritherapy                               1.205      3.337   1.295            8.595            0.4828   6.2298       0.0126

**Abbreviations:** OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit; SE, standard error.

###### 

Summary of adjusted means for MCS and PCS scores on bitherapy or tritherapy

                                 All insulin users                                               Uncontrolled bitherapy or tritherapy users       *P*-value
  ------------------------------ --------------------------------------------------------------- ------------------------------------------------ ------------
  **Adjusted means**                                                                                                                              
  Mental component summary       44.18                                                           45.83                                            0.2317
  Physical component summary     39.61                                                           40.09                                            0.6686
                                 **Early insulin initiation (≤5 years)**                         **Uncontrolled bitherapy or tritherapy users**   
                                                                                                                                                  
  **Mental component summary**   **42.85**                                                       **46.37**                                        **0.0304**
  Physical component summary     39.49                                                           40.35                                            0.5232
                                 **Early insulin initiation (≤5 years) with no complications**   **Uncontrolled bitherapy or tritherapy users**   
                                                                                                                                                  
  Mental component summary       44.88                                                           46.71                                            0.2945
  Physical component summary     42.94                                                           42.03                                            0.5748

**Note:** Data in bold is significant.

**Abbreviations:** MCS, Mental component summary; PCS, Physical component summary.
